Accord BioPharma, in Partnership with Foresee Pharmaceuticals, Launches CAMCEVI™ (Leuprolide) Injection Emulsion in the U.S. for the Treatment of Advanced Prostate Cancer in Adults

/PRNewswire/ -- Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd. focused on development of oncology, immunology, and critical care...

Related Keywords

Taipei ,T Ai Pei ,Taiwan ,Ben Chien ,Chrys Kokino ,Binish Chudgar ,Nuvan Dassanaike ,Pharmaceuticals On ,Pharmaceuticals Co Ltd ,Intas Pharmaceuticals Ltd ,Intas Pharmaceuticals ,Drug Administration ,Taipei Exchange ,Accord Biopharma ,New Drug Application ,Foresee Pharmaceuticals ,Stabilized Injectable Formulation ,Accord Healthcare ,Safety Information ,Visit Accordbiopharma ,Vice President Digital ,Marketing Strategy ,